Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 2/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016555 | 0.85 | CYP3A4 (0.51) | CYP3A4CYP2D6HPRT1P2RY1 | |
| SCHEMBL6016546 | 0.85 | CYP3A4 (0.51) | CYP3A4CYP2D6HPRT1P2RY1 | |
| SCHEMBL7148959 | 0.83 | CYP3A4 (0.49) | CYP3A4CYP2D6HPRT1POLB | |
| SCHEMBL6896822 | 0.82 | CYP3A4 (0.58) | CYP3A4CYP2D6HPRT1POLBP2RY1 | |
| SCHEMBL5810125 | 0.78 | POLB (0.59) | CYP3A4CYP2D6POLB | |
| SCHEMBL5810091 | 0.78 | POLB (0.59) | CYP3A4CYP2D6POLB | |
| SCHEMBL4312545 | 0.77 | CYP3A4 (0.73) | CYP3A4CYP2D6FAP | |
| SCHEMBL30515122 | 0.77 | CYP3A4 (0.73) | CYP3A4CYP2D6FAP | |
| SCHEMBL173030 | 0.77 | CYP3A4 (0.73) | CYP3A4CYP2D6FAP | |
| SCHEMBL1032335 | 0.77 | CYP3A4 (0.73) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187261-A1 | Purine derivatives, process for their preparation and use thereof | DCK, DTYMK, CCNK | CYP3A4 2631/4885CYP2D6 2882/4885HPRT1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.